Literature DB >> 22782020

Pancreatic surgery for adenocarcinoma.

Andrew L Warshaw1, Keith D Lillemoe, Carlos Fernandez-del Castillo.   

Abstract

PURPOSE OF REVIEW: Pancreatic resection remains among the most formidable and complex of abdominal surgical operations. Nonetheless, recent observations have continued to provide incremental improvement in both our evidence for treatment regimens and the technology, resulting in better outcomes. RECENT
FINDINGS: Neoadjuvant regimens appear to have promise, at least in local control and perhaps in long-term survival. More extensive operations focusing on perineural invasion along with minimally invasive laparoscopic and robotic techniques are attracting increasing attention. The effectiveness of major vascular resection remains controversial. Concentration of patients in centers of expertise has contributed to improved outcomes.
SUMMARY: Improved management of pancreatic resections for cancer with more extensive and less-invasive surgical techniques has increased the number of patients who are candidates for effective surgical treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22782020     DOI: 10.1097/MOG.0b013e3283567f2c

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  6 in total

1.  Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

Authors:  Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher
Journal:  HPB (Oxford)       Date:  2013-03-07       Impact factor: 3.647

Review 2.  Evolution and dynamics of pancreatic cancer progression.

Authors:  S Yachida; C A Iacobuzio-Donahue
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

3.  Factors Predictive of Reoperation After Pancreaticoduodenectomy for Pancreatic Cancer.

Authors:  Bradley R Hall; Richard Sleightholm; Lynette Smith; Harlan Sayles; Chandrakanth Are
Journal:  Indian J Surg Oncol       Date:  2019-03-25

4.  Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Authors:  T Dragovich; D Laheru; F Dayyani; V Bolejack; L Smith; J Seng; H Burris; P Rosen; M Hidalgo; P Ritch; A F Baker; N Raghunand; J Crowley; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-18       Impact factor: 3.333

Review 5.  Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications.

Authors:  John Chang; Donald Schomer; Tomislav Dragovich
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

6.  Pancreatic Surgery in the Older Population: A Single Institution's Experience over Two Decades.

Authors:  Bhaumik Brahmbhatt; Abhishek Bhurwal; Frank J Lukens; Mauricia A Buchanan; John A Stauffer; Horacio J Asbun
Journal:  Curr Gerontol Geriatr Res       Date:  2016-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.